Budget Impact Analysis of Spinal Muscular Atrophy Treatment in the Russian Federation
Author(s)
ABSTRACT WITHDRAWN
To conduct budget impact analysis (BIA) of spinal muscular atrophy (SMA) treatment in Russia. We conducted BIA for the treatment of SMA with two available at the moment of the study medicines – nusinersen and risdiplam through pharmacoeconomic model with time horizon up to 5 years. In Russia patients with SMA under 18 y.o. are covered by federal budget and patients of 18 y.o. and older by regional budget. We used tender prices for nusinersen and risdiplam for federal level computations and registered prices with VAT (10%) for regional calculations. Tender price per package for nusinersen was – $57546 for risdiplam – $9086, registered price with VAT for nusinersen was – $76728, for risdiplam was – $10513. Costs of treatment for risdiplam was calculated with respect to increase of body mass of patients, whereas costs for nusinersen consider period of initial treatment. Current patient distribution was 57,6% for nusinersen and 42,4% for risdiplam. Modelled situation had reversed distribution. Based on domestic epidemiological data total number of SMA patients under 18 y.o. was 1039, that already have been obtained treatment, 428 patients 18 y.o. and older, haven’t yet obtained treatment, also there was 191 newborn naïve incident patient every year. Discount rate was 3%. Exchange rate was: 1 USD = 73,67 Ruble. Five year total (federal and regional) budget for current distribution was $2,05 bln., and for modelled distribution was $2,09 bln. Cost-savings at current distribution was $43 mln. or 2,1%. Current distribution of patients with prevailing share of nusinersen provides cost-saving compare with modelling distribution, where risdiplam prevailed. Nusinersen is characterized by long term advantage from BIA perspective, with respect to longlife time of treatment, as it starts to provide cost-savings compare with risdiplam per patient at the patient’s age 23 months and older (body weight over 11,65 kg).
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
EE296
Topic
Economic Evaluation, Study Approaches
Topic Subcategory
Budget Impact Analysis, Decision Modeling & Simulation
Disease
Drugs